Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept conversion versus calcineurin inhibitor continuation in adolescent kidney transplant recipients
NL-OMON52226Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belatacept in end-stage kidney disease (ESKD) (2 arms), sponsored by Bristol Myers Squibb. Started Sep 2022; status: recruiting.
02
Drugs
belatacept
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON52226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52226.